ORIGENHuman Potential MeasuredYour protocol with Oura or WHOOP
A person before a stone threshold and a lake at dusk.

Sourced, not promised.

Research / Mental Work

Which supplements actually change HRV in trials, and what did Oura measure?

By Alejandro del Palacio · · 9 min read

The short answer

Two sources, not a ranking. In 100 healthy adults wearing an Oura, RMSSD in the magnesium L-threonate group separated from placebo (between-group p = 0.036), but the change within the active group was not significant (p = 0.270) (Lopresti & Smith 2026, manufacturer-funded). Omega-3 did not significantly change RMSSD across 15 randomized trials (Xin 2013).

Key findings

  • Two p-values, two readings. The between-group difference had p = 0.036. The change within the active group had p = 0.270 (Lopresti & Smith 2026).

  • The placebo moved too. Active: 44.62 to 46.07 ms (+1.45 ms, +3.2%). Placebo: 41.15 to 39.84 ms (-1.31 ms, p = 0.245) (Lopresti & Smith 2026).

  • Omega-3, no significant change in RMSSD. Fifteen pooled trials found no significant change in RMSSD (Xin 2013).

  • StatusEstimated

The myth: “Some supplements are proven to raise the HRV your ring measures”

Short answer: in the trials reviewed here, not clearly. With an Oura ring, RMSSD in the magnesium L-threonate group separated from placebo (p = 0.036), but its own change was not significant (p = 0.270), and the manufacturer funded the study (Lopresti & Smith 2026). Omega-3 did not significantly change RMSSD across 15 trials (Xin 2013).

In this article
  1. What does "changing HRV" mean, and what does an Oura ring measure?
  2. How was it measured in the Oura trial?
  3. Why do the between-group result and the active-group result tell different stories?
  4. What does omega-3 say about RMSSD?
  5. What can you measure with your ring?
  6. Where the evidence ends

What does "changing HRV" mean, and what does an Oura ring measure?

In a trial, "changing HRV" means moving one specific metric. It does not mean "improving" anything.

HRV is the general name for the variation between one heartbeat and the next. There are several ways to summarize it. Two show up here: RMSSD and high-frequency power, or HF.

RMSSD is a time-domain measure. It sums up how much the time between beats varies, from one beat to the next. The wearable data we work with is RMSSD or a derivative of it. In the trial we review, it was measured during sleep with an Oura ring.

HF power is a frequency-domain measure. It is used as a vagal marker. The sensor we work with does not report it.

A supplement can move one metric and leave the other still. If the study measures HF and the data you read is RMSSD, the two numbers are not talking about the same thing.

So, before you believe a headline, ask three questions:

  • Which metric was measured?
  • With which instrument?
  • In which population?

This article reviews two sources. The first is a 2026 trial that used an Oura ring in 100 healthy adults (Lopresti & Smith 2026). The second is a 2013 meta-analysis on omega-3 (Xin 2013).

It is not a ranking of supplements. It is a reading of what each study measured, and what it did not.

How was it measured in the Oura trial?

It was a randomized, double-blind, placebo-controlled trial. It had prospective registration. That means the plan was written down before the start, not after seeing the results.

It enrolled 100 healthy adults, aged 18 to 45, who reported being dissatisfied with their sleep. Anyone with a previously diagnosed disorder was excluded. This marks who the results resemble: healthy people in that age range who were unhappy with their sleep.

The active group took magnesium L-threonate (Magtein). The dose supplied 145 mg of elemental magnesium. The other group took placebo. The trial lasted 6 weeks.

The metric was RMSSD during sleep, measured with an Oura ring. That is useful because the instrument is a consumer device. It is the same kind of device you might wear.

Notice two design details. Double-blind means neither the participants nor the people assessing them knew who took what. The placebo is the point of comparison: it shows how RMSSD moves when the supplement is not taken. Without that group, we could not tell whether a change belongs to the supplement or simply to spending weeks under observation.

GroupBaseline (ms)Final (ms)Change (ms)pStatus
Active44.6246.07+1.450.270Estimated
Placebo41.1539.84-1.310.245Estimated
Between groups0.036Estimated

n = 100 · 6 weeks · Lopresti & Smith 2026 · trial funded by the manufacturer.

Why do the between-group result and the active-group result tell different stories?

Because they measure different things. The between-group comparison puts two changes side by side. The value within the active group looks only at its own before and after.

Start with the active group. Its RMSSD went from 44.62 to 46.07 ms. That is +1.45 ms, a rise of 3.2%. That change, on its own, was not significant (p = 0.270).

Now the placebo. Its RMSSD fell from 41.15 to 39.84 ms. That is -1.31 ms. It did not reach statistical significance either (p = 0.245).

The between-group difference did have p = 0.036. That separation comes from the drop in the placebo group (−1.31 ms). The active group's +1.45 ms was not significant.

This does not invalidate the result. But it changes how you read it. Saying "the supplement raised RMSSD" asks for more than the data supports. What you can say is this: the two groups already started at different values (44.62 and 41.15 ms), and what differed between them was how much each one changed (p = 0.036).

The trial lasted 6 weeks, or 42 days. The contrast comes from that end point.

The trial was funded by the manufacturer. That does not cancel anything. But it is a reason for another group, with no such tie, to repeat the measurement.

What does omega-3 say about RMSSD?

It says RMSSD does not change significantly. This is a meta-analysis of 15 randomized trials (Xin 2013).

The result has two parts. In the time domain, neither RMSSD nor SDNN, another measure in that domain, changed significantly. In the frequency domain, HF power did rise significantly.

The HF rise is a finding of the meta-analysis. But the sensor we work with does not report HF. Its data is RMSSD or a derivative of it.

So even if the effect on HF power is real, that sensor would not show it. And in RMSSD, the meta-analysis found no significant change.

We do not give the size of the HF rise: we did not extract it from the source.

If you want to go further on nights and resting heart rate, we have a separate note: how many nights it takes to judge omega-3 with resting heart rate.

What can you measure with your ring?

The trial measured RMSSD during sleep with an Oura ring. If you use Oura or WHOOP, what you have is a series of your own that you can read with method.

First, set a baseline: several nights before you change anything.

Second, look at the size. In the trial, the active group changed by +1.45 ms over 6 weeks (Lopresti & Smith 2026). That is +3.2%, below our threshold for HRV. That threshold is not a norm for other people.

Third, ask how far the metric has to move before it is worth believing. We explain it in another note: how much HRV has to change before it counts.

Fourth, change only one thing at a time. If you change several, you will not know which one moved what.

You can also see how your own data behaves against one specific supplement. We have a note on that with magnesium: what our thresholds say when the ring checks magnesium.

None of this tells you what to take. It is a way to read your own data.

And if your series shows nothing clear, that is also a data point. The sensor we work with does not report HF power, so an effect on that metric falls outside what it shows.

Where the evidence ends

These sources do not say as much as they seem to. Here is what they do not say:

  • Only one Oura trial is reviewed here. It had 100 healthy adults, aged 18 to 45, who reported being dissatisfied with their sleep. It does not speak to other ages. It does not speak to people with a previously diagnosed disorder, who were excluded.
  • The change within the active group was not significant (p = 0.270). You cannot say the supplement "raised" RMSSD by itself.
  • Part of the separation comes from the placebo, which fell 1.31 ms.
  • It is funded by the manufacturer. Without an independent replication, read it with caution.
  • In the same trial, the ring showed no group differences in sleep variables. That line is about the ring's sleep data only, not the questionnaires.
  • Omega-3: the meta-analysis sees no significant change in RMSSD. It pools 15 studies in humans, with variable doses over the short term. If the effect on HF is real, the sensor we work with does not show it.
  • This article does not compare supplements with each other. It does not say which to pick, how much, or whether it suits you. It is not medical advice.

What it means

This article reviews one trial with an Oura ring, in healthy adults aged 18 to 45, funded by the manufacturer. In it, RMSSD separated from placebo, but the change within the active group was not significant. For omega-3, the meta-analysis sees no significant change in RMSSD.

Read it as a lead with limits, not as a conclusion. If you use Oura or WHOOP, the most useful step is to measure your own series with method.

Notice: this is a measurement tool, not medical advice.

Quick questions

What does "changing HRV" mean, and what does an Oura ring measure?

In a trial, "changing HRV" means moving one specific metric. It does not mean "improving" anything. HRV is the general name for the variation between one heartbeat and the next. There are several ways to summarize it. Two show up here: RMSSD and high-frequency power, or HF. RMSSD is a time-domain measure.

How was it measured in the Oura trial?

It was a randomized, double-blind, placebo-controlled trial. It had prospective registration. That means the plan was written down before the start, not after seeing the results. It enrolled 100 healthy adults, aged 18 to 45, who reported being dissatisfied with their sleep.

Why do the between-group result and the active-group result tell different stories?

Because they measure different things. The between-group comparison puts two changes side by side. The value within the active group looks only at its own before and after. Start with the active group. Its RMSSD went from 44.62 to 46.07 ms. That is +1.45 ms, a rise of 3.2%.

What does omega-3 say about RMSSD?

It says RMSSD does not change significantly. This is a meta-analysis of 15 randomized trials (Xin 2013). The result has two parts. In the time domain, neither RMSSD nor SDNN, another measure in that domain, changed significantly. In the frequency domain, HF power did rise significantly.

What can you measure with your ring?

The trial measured RMSSD during sleep with an Oura ring. If you use Oura or WHOOP, what you have is a series of your own that you can read with method. First, set a baseline: several nights before you change anything. Second, look at the size.

Sources

  • Lopresti & Smith 2026, Frontiers in Nutrition · DOI
  • Xin 2013, American Journal of Clinical Nutrition · PubMed

Keep reading:

Alejandro del PalacioAuthor · reviewed on 2026-11-17

ORIGENHuman Potential Measured

pieza_id p1-supplements-for-hrv-ring-trials